BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35429078)

  • 1. lncRNA MIAT targets miR-411-5p/STAT3/PD-L1 axis mediating hepatocellular carcinoma immune response.
    Zhang X; Pan B; Qiu J; Ke X; Shen S; Wang X; Tang N
    Int J Exp Pathol; 2022 Jun; 103(3):102-111. PubMed ID: 35429078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. lncRNA MIAT promotes proliferation and invasion of HCC cells via sponging miR-214.
    Huang X; Gao Y; Qin J; Lu S
    Am J Physiol Gastrointest Liver Physiol; 2018 May; 314(5):G559-G565. PubMed ID: 29097358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression.
    Peng L; Pan B; Zhang X; Wang Z; Qiu J; Wang X; Tang N
    Cell Biol Toxicol; 2022 Dec; 38(6):1159-1173. PubMed ID: 35438468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HOXA-AS3 Promotes Proliferation and Migration of Hepatocellular Carcinoma Cells via the miR-455-5p/PD-L1 Axis.
    Zeng C; Ye S; Chen Y; Zhang Q; Luo Y; Gai L; Luo B
    J Immunol Res; 2021; 2021():9289719. PubMed ID: 34988230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long noncoding RNA EPB41L4A-AS2 inhibits hepatocellular carcinoma development by sponging miR-301a-5p and targeting FOXL1.
    Wang YG; Wang T; Shi M; Zhai B
    J Exp Clin Cancer Res; 2019 Apr; 38(1):153. PubMed ID: 30971290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KCNQ1OT1 sponges miR-34a to promote malignant progression of malignant melanoma via upregulation of the STAT3/PD-L1 axis.
    Wang X; Ren Z; Xu Y; Gao X; Huang H; Zhu F
    Environ Toxicol; 2023 Feb; 38(2):368-380. PubMed ID: 36399467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA DARS-AS1 aggravates the growth and metastasis of hepatocellular carcinoma via regulating the miR-3200-5p-Cytoskeleton associated protein 2 (CKAP2) axis.
    Feng Y; Wei G; Zhang L; Zhou H; Wang W; Guo P; Cheng C; Ji L; Cai Q; Feng Y; Tu H
    Bioengineered; 2021 Dec; 12(1):8217-8232. PubMed ID: 34596006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3.
    Li Y; Zhou T; Cheng X; Li D; Zhao M; Zheng WV
    Bioengineered; 2022 Mar; 13(3):4730-4743. PubMed ID: 35184646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells.
    Liu Z; Ning F; Cai Y; Sheng H; Zheng R; Yin X; Lu Z; Su L; Chen X; Zeng C; Wang H; Liu L
    Cancer Commun (Lond); 2021 Jan; 41(1):62-78. PubMed ID: 34236149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA MIAT correlates with immune infiltrates and drug reactions in hepatocellular carcinoma.
    Peng L; Chen Y; Ou Q; Wang X; Tang N
    Int Immunopharmacol; 2020 Dec; 89(Pt A):107071. PubMed ID: 33221703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas.
    Yoon CJ; Chang MS; Kim DH; Kim W; Koo BK; Yun SC; Kim SH; Kim YS; Woo JH
    Gastric Cancer; 2020 Sep; 23(5):780-795. PubMed ID: 32206940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma.
    Fan F; Chen K; Lu X; Li A; Liu C; Wu B
    Hepatol Int; 2021 Apr; 15(2):444-458. PubMed ID: 33219943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of LncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma.
    Ma J; Li T; Han X; Yuan H
    J Cancer Res Clin Oncol; 2018 Feb; 144(2):205-214. PubMed ID: 29127494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRNDE-h transcript/miR-136-5p axis regulates interleukin enhancer binding factor 2 expression to promote hepatocellular carcinoma cell proliferation.
    Shiu TY; Lin HH; Shih YL; Feng AC; Huang HH; Huang TY; Hsieh CB; Chang WK; Hsieh TY
    Life Sci; 2021 Nov; 284():119708. PubMed ID: 34153299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-506 Promotes Natural Killer Cell Cytotoxicity against Human Hepatocellular Carcinoma Cells by Targeting STAT3.
    Su Z; Ye X; Shang L
    Yonsei Med J; 2019 Jan; 60(1):22-29. PubMed ID: 30554487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of lncRNA SBF2-AS1 inhibits hepatocellular carcinoma proliferation and migration by regulating the miR-361-5p/TGF-β1 signaling pathway.
    Wu YH; Yu B; Chen WX; Ai X; Zhang W; Dong W; Shao YJ
    Aging (Albany NY); 2021 Aug; 13(15):19260-19271. PubMed ID: 34341185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
    Wang Y; Cao K
    J Immunol Res; 2021; 2021():9965099. PubMed ID: 34307695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
    Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long non-coding RNAFOXD1-AS1 modulated CTCs epithelial-mesenchymal transition and immune escape in hepatocellular carcinoma in vitro by sponging miR-615-3p.
    Guo BL; Zheng QX; Jiang YS; Zhan Y; Huang WJ; Chen ZY
    Cancer Rep (Hoboken); 2024 Mar; 7(3):e2050. PubMed ID: 38517478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA NUTM2A-AS1 aggravates the progression of hepatocellular carcinoma by activating the miR-186-5p/KLF7-mediated Wnt/beta-catenin pathway.
    Long J; Liu L; Yang X; Zhou X; Lu X; Qin L
    Hum Cell; 2023 Jan; 36(1):312-328. PubMed ID: 36242728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.